𝔖 Bobbio Scriptorium
✦   LIBER   ✦

α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b

✍ Scribed by Hui Ma; JiangHua Wang; Fang Guo; Lai Wei

Book ID
107349886
Publisher
Science in China Press (SCP)
Year
2011
Tongue
English
Weight
719 KB
Volume
54
Category
Article
ISSN
1674-7305

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon α-2b with and without ribavir
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study
✍ Chun-Jen Liu; Ming-Yang Lai; You-Chen Chao; Li-Ying Liao; Sien-Sing Yang; Tun-Je 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

To study whether interferon (IFN) ␣ and ribavirin combination therapy has a beneficial effect for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, we enrolled 119 such patients in a randomized study. Fifty-nine patients received 5 million units of IFN-␣2b daily for 4 weeks followed by 5 m

A randomized controlled trial of thymosi
A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B
✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission